Sloan Sheldon has filed 3 insider transactions across 1 company since October 2024.
Most recent transaction: a grant/award of 140000 shares of Spyre Therapeutics, Inc. ($SYRE) on January 09, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 9, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | A | Stock Option (Right to Buy) | 140000 | $0.00 | 140,000.0000 | 77,592,130 | 9999.99% | 0.18% |
| Jan. 15, 2025 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | A | Stock Option (Right to Buy) | 95500 | $0.00 | 95,500.0000 | 0 | 9999.99% | 0.00% |
| Oct. 1, 2024 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 0 | 9999.99% | 0.00% |